A Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized, Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Mild to Moderate Atopic Dermatitis

Trial Profile

A Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized, Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Mild to Moderate Atopic Dermatitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2018

At a glance

  • Drugs B 244 (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions
  • Sponsors AOBiome
  • Most Recent Events

    • 01 Aug 2018 Planned End Date changed from 1 Jul 2018 to 1 Apr 2019.
    • 01 Aug 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Dec 2018.
    • 23 Jan 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top